MAIA Biotechnology, Inc.

MAIA
NYSE AmericanBiotechnology

-75.0%

since IPO

IPO Price

$5.00

Current Price

$1.25

Return

-75.0%

Market Cap

$75.8M

IPO Date

Jul 28, 2022

Lockup End

Jan 24, 2023

Lockup Status

Lockup expired 1191days ago

Price Performance

Stock price vs IPO price over time (sample data)

Stock Price
IPO Price
Lockup End

Performance Summary

First Day
N/A
1 Month
N/A
3 Months
N/A
6 Months
N/A
1 Year
N/A
Since IPO
-75.0%

MAIA Biotechnology, Inc. (MAIA) — IPO Analysis

By Kian O Connor | Updated 4/29/2026

Company Overview

MAIA Biotechnology, Inc. (ticker: MAIA) specializes in operational efficiency while maintaining strategic capabilities in core business operations, positioning itself within the Biotechnology sector through strategic positioning and cost-effective alternatives. The company has developed its operations around customer satisfaction, creating market differentiation through specialized expertise and managed service agreements that supports sustainable growth and customer relationship development. The company completed its public offering on 2022-07-28, accessing capital markets during sustainability requirement increases within the Biotechnology landscape. The IPO timing reflected the company's strategic positioning and growth trajectory, with market reception emphasizing management's execution capabilities and the company's approach to operational efficiency as key value creation drivers in an evolving competitive environment. Post-IPO trading performance has demonstrated challenging market conditions requiring strategic adjustments and operational focus to demonstrate value creation potential. Market assessment focuses on the company's strategic positioning and strategic emphasis on core business operations as indicators of long-term competitive positioning within the Biotechnology sector, with investors evaluating operational execution and market opportunity capture relative to industry development trends. The lockup period expires April 11, 2023, providing market insights into management and early investor confidence in strategic direction and competitive positioning. Given the company's focus on operational efficiency and emphasis on customer satisfaction, insider trading decisions will likely reflect assessments of execution progress, competitive dynamics, and growth opportunity realization within the evolving Biotechnology market landscape.

Performance Overview

Since going public at $5.00 per share on Jul 28, 2022, MAIA Biotechnology, Inc. shares have declined 75.0%, disappointing investors who participated in the IPO. The stock currently trades at $1.25, giving the company a market capitalization of $75.8M.

Lockup Expiration

The lockup period for MAIA Biotechnology, Inc. expired 1191 days ago on Jan 24, 2023. Insiders and early investors are now free to sell their pre-IPO shares. The post-lockup trading period is often volatile as the market absorbs any additional supply from insider selling.

Industry Context

MAIA Biotechnology, Inc. operates in the Biotechnology sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing MAIA as an investment.

Trading History

MAIA Biotechnology, Inc. is actively trading in the public markets with a current share price of $1.25. The company went public at $5.00 per share, representing a decline of 75.0% from the initial offering price. With a current market capitalization of $75.8M, MAIA Biotechnology, Inc. continues to establish its presence as a publicly traded entity in the Biotechnology.

Important Disclaimer

This analysis of MAIA Biotechnology, Inc. (MAIA) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.

Insider Selling Activity

Estimated insider trading activity around lockup expiry period (sample data)

3
Pre-Expiry Average
Minimal
90
Expiry Day
Very High
55
Post-Expiry (30d)
High

Activity Heatmap

60 days before/after lockup expiry
Intensity Scale:
Minimal
Low
Moderate
High
Very High
Lockup Expiry

About This Data

This heatmap shows estimated insider selling activity based on typical patterns around lockup expiry periods. Actual data would be derived from SEC Form 4 filings. Higher intensity indicates more insider transactions, which may correlate with increased selling pressure and potential stock price volatility.

Related IPOs

TickerCompanyIndustryIPO DateIPO PriceCurrentReturn
EVMNEvommune, Inc.BiotechnologyNov 6, 2025$16.00$25.58+59.9%
MPLTMapLight Therapeutics, Inc.BiotechnologyOct 27, 2025$17.00$30.31+78.3%
LBRXLB Pharmaceuticals IncBiotechnologySep 11, 2025$15.00$31.38+109.2%
CURXCuranex Pharmaceuticals IncBiotechnologyAug 26, 2025$4.00$0.43-89.3%
CAICaris Life Sciences, Inc.BiotechnologyJun 18, 2025$21.00$18.44-12.2%
MENSJyong Biotech Ltd.BiotechnologyJun 17, 2025N/A$2.17N/A
AARDAardvark Therapeutics, Inc.BiotechnologyFeb 13, 2025$16.00$5.59-65.1%
SIONSionna Therapeutics, Inc.BiotechnologyFeb 7, 2025$18.00$39.59+119.9%

Related IPO Analysis

KO
By • Founder & Data Analyst